X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Endocrine Metabolic & Immune Disorders-Drug Targets

期刊標題檢索 ENDOCR METAB IM 最新評論: This journal is too rubbish. I have decided to withdraw the submission... (2025-07-26)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Endocrine Metabolic & Immune Disorders-Drug Targets]您好,您是該頁面的第 21804 位訪客。

期刊簡介
期刊名稱Endocrine Metabolic & Immune Disorders-Drug Targets Endocrine Metabolic & Immune Disorders-Drug Targets
LetPub Score
5.3
50 ratings
Rate

Reputation
6.3

Influence
3.8

Speed
8.5

期刊簡稱ENDOCR METAB IMMUNE
ISSN1871-5303
E-ISSN2212-3873
h-index44
CiteScore
CiteScoreSJRSNIPCiteScore Rank
4.400.5350.547
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Endocrinology, Diabetes and Metabolism
Q2124 / 247
Category: Medicine
Subcategory: Immunology and Allergy
Q3131 / 231

自引率 (2023-2024)5.00%自引率趨勢
掲載範囲
Aims & Scope

This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.
官方網站http://benthamscience.com/journal/index.php?journalID=emiddt
在線稿件提交http://bsp-cms.eurekaselect.com/index.php/CDTIEMD
開放訪問No
出版商Bentham Science Publishers B.V.
主題領域ENDOCRINOLOGY & METABOLISMIMMUNOLOGY
出版國/地區U ARAB EMIRATES
發行頻率
創刊年0
每年文章數233每年文章數趨勢
黃金OA百分比3.91%
Web of Science 四分位
2023-2024
WOS Quartile: Q3

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ENDOCRINOLOGY & METABOLISMSCIEQ3141/191
IMMUNOLOGYSCIEQ4143/183
PHARMACOLOGY & PHARMACYSCIEQ3232/352
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1871-5303%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據:
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Endocrine Metabolic & Immune Disorders-Drug Targets】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Science ImmunologyH-index: 0

    CiteScore: 26.90
    Journal of Allergy and Clinical Immunology-In PracticeH-index: 40

    CiteScore: 11.00
    Cancer Immunology ResearchH-index: 62

    CiteScore: 12.80
    npj VaccinesH-index: 8

    CiteScore: 11.60
    OncoImmunologyH-index: 58

    CiteScore: 12.90
    OncoImmunologyH-index: 49

    CiteScore: 12.90
    HLAH-index: 93

    CiteScore: 2.50
    ALLERGOLOGY INTERNATIONALH-index: 45

    CiteScore: 10.40
    Immunity & AgeingH-index: 38

    CiteScore: 8.40
    Clinical and Translational AllergyH-index: 28

    CiteScore: 7.10
    學科內最受檢索的期刊 頁面查看次數
    OncoImmunology101177
    Journal of Inflammation Research76150
    Cancer Immunology Research66854
    OncoImmunology51473
    Science Immunology41538
    npj Vaccines31122
    Human Vaccines & Immunotherapeutics25864
    Human Vaccines & Immunotherapeutics25827
    Journal of Allergy and Clinical Immunology-In Practice19878
    Allergy Asthma & Immunology Research19811
  •  

    Endocrine Metabolic & Immune Disorders-Drug Targets Endocrine Metabolic & Immune Disorders-Drug Targets
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Endocrine Metabolic & Immune Disorders-Drug Targets] 的評論撰寫評論
作者: 666HSGDRH


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2025-07-26 12:56:10 評論於
This journal is too rubbish. I have decided to withdraw the submission. It's a 2-point magazine with too many requirements. I just submitted the manuscript, and the editors haven't even got their hands on it yet. They are already asking for language editing and requesting payment to improve the quality of the images on their official website. To put it bluntly, it's just a money pit. There is no guarantee that the text will even be sent for review, and there are a lot of issues to deal with.
(0) 讚! | 666HSGDRH

作者: 666HSGDRH


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2025-07-25 16:12:12 評論於
Hello, have you received an email from me during the initial submission process stating: "The manuscript must be carefully reviewed by an independent individual proficient in English. In this regard, we ask that you provide a certificate signed by a person who has checked your manuscript for grammar errors. Once you provide the certificate, we will proceed with further processing of the submission for peer review. However, if you believe your English is proficient, a signed declaration from you will suffice." How should we proceed with this? Should we reply to the email? Is there a template available? Thank you.
(0) 讚! | 666HSGDRH

作者: Xue-Accepeted


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2025-07-04 10:15:10 評論於
May I ask how the article progresses from here?
(0) 讚! | Xue-Accepeted

作者: Xue-Accepeted


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2025-07-04 10:13:29 評論於
Hello, I would like to ask about the approximate timeline for submitting contributions.
(0) 讚! | Xue-Accepeted

作者: Xue-Accepeted


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2025-07-04 10:01:35 評論於
Hello, I would like to ask about the approximate timeline for submissions. Currently, my status is "Awaiting Editorial Approval" and it has not changed for 4 days.
(0) 讚! | Xue-Accepeted

作者: 请勿匆匆


領域: 医学
審稿時間: 5.0 month(s)
結果: 修改後接受


撰寫評論

2025-06-03 14:42:51 評論於
It is a paid magazine, 1590 USD. If you want to submit for free, please be careful. Overall, the review comments are quite friendly, and the revised version will be accepted directly. I thought it was a non-IA magazine, and I can't afford the page charge. I have written an email requesting a reduction or waiver. If not possible, I will have to withdraw the submission.
(0) 讚! | 请勿匆匆

作者: keyanlabourer


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-09-10 13:32:38 評論於
One meta-analysis, submitted on April 13th, revised on August 23rd, accepted on September 27th, with excellent editing and ongoing positive communication with the editor.
(0) 讚! | keyanlabourer

作者: YSL


領域: 医学
審稿時間: 5.0 month(s)
結果: 修改後接受


撰寫評論

2018-08-28 17:42:03 評論於
The number of papers published each year is low, so it is not easy to get accepted here. The reviewers asked some questions that are not easy to answer.

(0) 讚! | YSL

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Endocrine Metabolic & Immune Disorders-Drug Targets] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*